More on AKBA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.70 |
|
|||
| Open | $0.70 | ||||
| 52 Wk High | $13.20 | ||||
| 52 Wk Low | $7.00 | ||||
| Day High | $0.73 | ||||
| Day Low | $0.67 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 7,127,167 | ||||
- Form 8-K Akebia Therapeutics, For: Oct 07
- Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
- Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Akebia doses first patient in Phase 2 kidney disease trial
- Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Form 4 Akebia Therapeutics, For: Aug 06 Filed by: Butler John P.
- Leerink Downgrades Akebia Therapeutics (AKBA) to Market Perform
- H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
Entities mentioned with AKBA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Needham & Company | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
